Search research articles
Contact Us
Filters
Showing results (151-160 of 226) with videos related to
Page
of 23
Sort By:
JCO Precision Oncology
|
May 26, 2021
Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma
Eddy C Hsueh, James R DeBloom, Jonathan H Lee, et al.
Journal of Surgical Oncology
|
September 17, 2022
Regional control after precision lymph node dissection for clinically evident melanoma metastasis
Kevin T Lynch, Yinin Hu, Norma E Farrow, et al.
Cancer Drug Resistance (Alhambra, Calif.)
|
September 30, 2022
A nano-enhanced vaccine for metastatic melanoma immunotherapy
Katelyn E Salotto, Walter C Olson, Karlyn E Pollack, et al.
Cancer Immunology Research
|
August 20, 2021
Characteristics of Immune Memory and Effector Activity to Cancer-Expressed MHC Class I Phosphopeptides Differ in Healthy Donors and Ovarian Cancer Patients
Amanda M Lulu, Kara L Cummings, Erin D Jeffery, et al.
Journal for Immunotherapy of Cancer
|
May 1, 2020
Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment
Karlyn E Pollack, Max O Meneveau, Marit M Melssen, et al.
BMC Cancer
|
December 6, 2008
The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines
Donna H Deacon, Kevin T Hogan, Erin M Swanson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2011
Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups
Anneke T Schroen, Gina R Petroni, Hongkun Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 12, 2009
Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial
Craig L Slingluff, Gina R Petroni, Walter C Olson, et al.
Oncoimmunology
|
October 6, 2018
Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma
Marit M Melssen, Walter Olson, Nolan A Wages, et al.
Science Immunology
|
January 27, 2019
Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8<sup>+</sup> T cells
Lelisa F Gemta, Peter J Siska, Marin E Nelson, et al.
Page
of 23
Search research articles
Search
Showing results (151-160 of 226) with videos related to
Sort By:
Page
of 23
JCO Precision Oncology
|
May 26, 2021
Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma
Eddy C Hsueh, James R DeBloom, Jonathan H Lee, et al.
Journal of Surgical Oncology
|
September 17, 2022
Regional control after precision lymph node dissection for clinically evident melanoma metastasis
Kevin T Lynch, Yinin Hu, Norma E Farrow, et al.
Cancer Drug Resistance (Alhambra, Calif.)
|
September 30, 2022
A nano-enhanced vaccine for metastatic melanoma immunotherapy
Katelyn E Salotto, Walter C Olson, Karlyn E Pollack, et al.
Cancer Immunology Research
|
August 20, 2021
Characteristics of Immune Memory and Effector Activity to Cancer-Expressed MHC Class I Phosphopeptides Differ in Healthy Donors and Ovarian Cancer Patients
Amanda M Lulu, Kara L Cummings, Erin D Jeffery, et al.
Journal for Immunotherapy of Cancer
|
May 1, 2020
Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment
Karlyn E Pollack, Max O Meneveau, Marit M Melssen, et al.
BMC Cancer
|
December 6, 2008
The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines
Donna H Deacon, Kevin T Hogan, Erin M Swanson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2011
Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups
Anneke T Schroen, Gina R Petroni, Hongkun Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 12, 2009
Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial
Craig L Slingluff, Gina R Petroni, Walter C Olson, et al.
Oncoimmunology
|
October 6, 2018
Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma
Marit M Melssen, Walter Olson, Nolan A Wages, et al.
Science Immunology
|
January 27, 2019
Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8<sup>+</sup> T cells
Lelisa F Gemta, Peter J Siska, Marin E Nelson, et al.
Page
of 23